Kudos to DeeDee!!!!!
The NIH is beginning to react and will continue to react to the accelerating progress in Regenerative Medicine, Advanced Medical Materials, and Proteomics.
And 5 or 7 years ago this would have been useful to ACTC. But at this stage, this will not at all be of any significant value to ACTC. This will off course help new struggling companies, but I do not put much value to this effort in terms of its impact to ACTC.
The fact is NIH is too late, and by the time they get going... ACTC will be well on its way to opening up the door of Regenerative Medicine.
The only thing that this might help is in focusing its funding of New Companies. But I doubt that it will help at all on other areas. It is still in fact, a Government Entity, and will carry the same baggage as any government entity. In fact, it may end up confusing its boundaries relative to the FDA.
ACTC moving forward is better off concentrating on its relationship with the FDA, and then after two years, taking another look at this new NIH Working Group Center, they can make an assessment of its usefulness.
Right now, ACTC's single minded focus should be in accelerating its trials, its product development programs, its JVs, its patents, and its Roslin Strategy.
NIH will try to restructure to be relevant in the coming century but it will always be behind ACTC by at least 5-10 years.
I do not think the government, and the market, and the Public is even remotely close to understanding
ACTC's coming role and dominance in Regenerative Medicine. Roche, Pfizer, Novartis, and the Chinese are accutely aware of this now. And of all people, take a look at the demeanor and posture and tone of Dr. Schwartz relative to his comments in July before the first dosing and his latest comment during his
Mesa presentations. It is Night and Day!
So in simple terms, this Collins proposal could take years to get funded and implemented, and you can bet that Congress, the Universities, and every stakeholders of NIH will try to influence its final structure. In the end, it will still be a mess.
So do I think it will help the Orphan Drug Market? Maybe. But I do not think so.
Will it impact ACTC at all? I do not think so.
The NIH will sway with the Politics of the Day. So it will swing between Adult Stem Cells and play lip service to hESCs, that is until they realize that hESCs work! I do not really care if they revised their guidelines. But they will, when the blind can see! LOL!
And now on the Delay, Government delay is just that... government delay. The explanation is everything that you can think is derogatory about the government will explain any delay... from simple stupidity to Machiavellian conspiracy will be an appropriate explanation for the NIH delay of the redefinition. LOL!
I hope the rest of the readers here will make their opinions be known to DeeDee.